Vivesto AB (LON: 0N4A)

Market Cap	9.20M
Revenue (ttm)	486.40K
Net Income (ttm)	-6.87M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,440
Average Volume	3,455
Open	0.264
Previous Close	0.268
Day's Range	0.264 - 0.264
52-Week Range	0.215 - 0.494
Beta	0.05
RSI	37.18
Earnings Date	Feb 20, 2025

About Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company’s products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encaps...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1988
• Employees: 14
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0N4A

Financial Performance

In 2023, Vivesto AB's revenue was 6.61 million, an increase of 117.50% compared to the previous year's 3.04 million. Losses were -128.74 million, -63.90% less than in 2022.

Financial numbers in SEK